The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis
Perry RJ1. Obesity (Silver Spring). 2019 Jul 25. doi: 10.1002/oby.22559. [Epub ahead of print]
Author information
1 Departments of Internal Medicine and Cellular & Molecular Physiology, Yale University, New Haven, Connecticut, USA.
Abstract
Concordant with soaring obesity rates, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liverdisease in the world. The obesity epidemic demands interventions to reverse obesity-associated hepatic steatosis, NAFLD, and nonalcoholic steatohepatitis, and several new pharmacologic approaches have been developed within the past several years. Steatosis develops when energy delivery to the liver, modulated by rates of hepatic lipogenesis, exceeds the capacity of the liverto utilize or export this energy. Therefore, pharmacologic approaches to reverse hepatic steatosis have focused largely, though not exclusively, on (1) reducing substrate availability to the liver, (2) reducing hepatic lipid synthesis, and (3) increasing hepatic mitochondrial fat oxidation (Figure 1). This Perspective will discuss these three classes of emerging pharmacologic therapies against hepatic steatosis, with the ultimate intent to ameliorate NAFLD and/or nonalcoholic steatohepatitis, and the advantages and pitfalls afforded by each strategy to treat these epidemics of obesity-associated liver disease.